地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:17754422825
传真:15172469628
邮箱:sales@amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://antibody.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

SERO生产以下系列专利产品Seronorm™, Pathonorm™ and Autonorm™。除此之外,也为客户提供个性化定制产品。
Seronorm™系列
主要产品包括免疫对照,结合激素,心脏和肿瘤标志物,Seronorm™所有对照血清来源为人,不含防腐剂和稳定剂,产品文档全面,为市场上最常用的仪器提供超过50种分析物的分配值,可提供四个不同临床级别,且每一级别都可单独提供。Seronorm™ Immunoassay Liq low – 含有与临床相当的低水平的醛固酮,雄烯二酮,皮质醇,铁蛋白,IgE,17-OH-孕酮,PSA总量,睾酮,游离T4,TSH,25-OH-维生素D和维生素B12
Pathonorm™ and Autonorm™
Pathonorm™临床化学级对照,不含防腐剂和稳定剂的动物血清,适合大部分临床化学分析,为市面上常用仪器提供超过38种分析物的分配值,有两种临床级别,且都可以单独提供,产品以冻干粉形式提供,货架期长。
Autonorm™
满足绝大部分临床化学实验室正常水平的分析级的高品质对照,不含防腐剂和稳定剂的动物血清,不含Pharmaca。文档齐全,为市场上最常用的仪器提供超过30种分析物的分配值,冻干粉,货架期长。
客户定制产品:
SERO也针对有质量意识的诊断公司,组织提供定制服务,SERO可定制的高品质对照产品如下:
常规血清化学(人或动物基质)
常规尿液化学
脂质
激素
肿瘤标记
心脏标志物
蛋白质
治疗药物
专业和护理点控制(CRP,HbA1C,血红蛋白,葡萄糖)
微量元素和重金属
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://antibody.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="SERO"> SERO
艾美捷科技代理BioGenex品牌产品。
Biogenex位于美国旧金山,是抗原修复的发明者,是致力于研发生产准确、可靠、可重复性的高效检测方法的自动化和标准化的先驱。BioGenex拥有全面的免疫组化全自动处理系统,包括i1000抗原修复系统、i6000自动染色仪、iVISION数码成像分析系统等,具有检测诊断的高度一致性,为科研和临床诊治提供高质量的参考依据。Biogenx i 系列免疫组化全自动处理系统是使您的科研和临床病理诊断国际化的最佳途径。
BioGenex is a global market leader and an innovator in providing customer-centric molecular pathology solutions and complete walk-away automation of cell and tissue staining. We develop, manufacture and market automated slide-based staining instruments and offer a broad range of histology products for immunohistochemistry (IHC), in-situ hybridization (ISH), miRNA, in situ PCR.
BioGenex的主要产品包括:
(1)IHC
Automation
Primary Antibodies
Antigen Retrieval & Dewax
Detection Systems
Controls
Ancillaries
(2)ISH/CISH
Automation
ISH/CISH Probes
Nucleic Retrieval & Dewax
Detection Systems
Ancillaries
(3)FISH
eFISH Automation
eFISH Probes
Nucleic Retrieval & Dewax
eFISH Visualization Kits
eFISH Ancillaries
(4)miRNA
miRNA Automation
miRNA Probes & Controls
Nucleic Retrieval & Dewax
Detection Systems
Ancillaries
(5)Multiplexing & Double Staining
Automation
Antibody Cocktails
Multiplexing
Antigen Retrieval & Dewax
Detection Systems
Ancillaries
(6)Special Stains
Automation
Special Stains
Ancillaries
(7)In Situ PCR
(8)1IF
" data-original="http://antibody.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理BioGenex品牌产品"> 艾美捷科技代理BioGenex品牌产品
艾美捷科技有限公司代理SIRIUS FINE CHEMICALS SICHEM GMBH公司产品。
SIRIUS FINE CHEMICALS SICHEM GMBH公司,主要提供:
点击化学工具(Si-CLICK (Click Chemistry))
PEG试剂(Si-PEGs)
脂质及其衍生物(Si-LIPs (Lipids & Derivatives))
磷酸肌醇试剂(Inositol Phosphates & Phosphoinositides)
核酸及其衍生物(Nucleotides & Derivatives)
API标准品及代谢底物(API Standards & Metabolites)
稳定的同位素(Stable Isotopes)
磷酸化及亚磷酸化试剂(Phosphorylation / Phosphitylation)
精细化学试剂(Fine Chemicals)
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
产品列表
| 产品名称 | 产品编号 | 分子式 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4/EQ) / EQUATORIAL isomer | SC-8060 | C15H26N2O4 |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Click Amino Acid / exo-BCN – Fmoc – L - Lysine (BCN) | SC-8038 | C32H36N2O6 |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| Click-Amino-Acid / N3-Lys | SC-8027 | C9H17N5O4 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
| Click Amino Acid / endo-BCN – Fmoc – L - Lysine (BCN) | SC-8015 | C32H36N2O6 |
| Click Amino Acid / trans-Cyclooct-2-en – L - Lysine (TCO*A) | SC-8008 | C15H26N2O4 |
| Click Amino Acid / exo BCN - L - Lysine | SC-8016 | C17H26N2O4 |
| Click Amino Acid / Norbonene-CH2 – L - Lysine (NBO) | SC-8006 | C15 H24 N2 O4 * HCl |
| Click Amino Acid / rac BCN - L - Lysine | SC-8003 | C17H26N2O4 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4) / AXIAL isomer | SC-8004 | C15H26N2O4 |
| Click Amino Acid / endo BCN - L - Lysine | SC-8014 | C17H26N2O4 |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Click Amino Acid (99%) / SCO - L - Lysine - HCO2H-salt | SC-8001 | C15H24N2O4* HCO2H |
| Click Amino Acid (95%) / SCO - L - Lysine - HCO2H-salt | SC-8000 | C15H24N2O4 * HCO2H |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| exo-BCN-NHS carbonate | SC-8075 | C15H17NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| exo BCN - OH | SC-8033 | C10 H14 O |
| SCO - active ester (p-NPE) | SC-8032 | C15H15NO5 |
| SCO - OH | SC-8030 | C8H12O |
| endo BCN - OH | SC-8029 | C10 H14 O |
| exo BCN - active ester (p-NPE) | SC-8010 | C17H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| (E)-cyclooct-4-enol / axial - TCO4 / A | SC-8018 | C8H14O |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| (E)-cyclooct-4-en active ester / TCO/E- active ester (p-NPE) / equatorial | SC-8024 | C15H17NO5 |
| (E)-cyclooct-4-en active ester / TCO4 / A- active ester (p-NPE) / axial | SC-8019 | C15H17NO5 |
| TCO*A - active ester (p-NPE) | SC-8007 | C15H17NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Aminopentyl - Tetrazine - HCl-salt | SC-1193 | C18H20N8O * HCl |
| Tetrazine active ester (Tetrazine-NHS) | SC-1194 | C17H11N7O4 |
| Aminopropyl - Tetrazine - HCl-salt | SC-1192 | C16H16N8O * HCl |
| Methyl-Tetrazine - Amine- HCO2H-salt | SC-1191 | C10H11N5* HCO2H |
| Tetrazine - Amine - HCO2H-salt | SC-1190 | C9H9N5 * HCO2H |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| Bis-Cyano-PEG9 | SC-8932 | C22H40N2O9 |
| Bis-Cyano-PEG5 | SC-8931 | C14H24N2O5 |
| Bis-Cyano-PEG4 | SC-8930 | C12H20N2O4 |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| TAMRA-PEG8-COOH | SC-8711 | C44H59N3O14 |
| TAMRA-PEG4-COOH | SC-8710 | C36H43N3O10 |
| TAMRA-PEG3-COOH | SC-8709 | C34H39N3O9 |
| TAMRA-PEG8-NHS | SC-8708 | C48H62N4O16 |
| TAMRA-PEG4-NHS | SC-8707 | C40H46N4O12 |
| TAMRA-PEG3-NHS | SC-8706 | C38H42N4O11 |
| TAMRA-PEG7-Maleimide | SC-8705 | C48H61N5O14 |
| TAMRA-PEG3-Maleimide | SC-8704 | C40H45N5O10 |
| TAMRA-PEG2-Maleimide | SC-8703 | C38H41N5O9 |
| TAMRA-PEG7-NH2 | SC-8702 | C41H56N4O11 |
| TAMRA-PEG3-NH2 | SC-8701 | C33H40N4O7 |
| TAMRA-PEG2-NH2 | SC-8700 | C31H36N4O6 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Biotin-PEG8-COOH | SC-8611 | C29H53N3O12S |
| Biotin-PEG4-COOH | SC-8610 | C19H33N3O7S |
| Biotin-PEG3-COOH | SC-8609 | C19H33N3O7S |
| Biotin-PEG8-NHS | SC-8608 | C33H56N4O14S |
| Biotin-PEG4-NHS | SC-8607 | C25H40N4O10S |
| Biotin-PEG3-NHS | SC-8606 | C23H36N4O9S |
| Biotin-PEG7-Maleimide | SC-8605 | C33H55N5O12S |
| Biotin-PEG3-Maleimide | SC-8604 | C25H39N5O8S |
| Biotin-PEG2-Maleimide | SC-8603 | C23H35N5O7S |
| Biotin-PEG7-NH2 | SC-8602 | C26H50N4O9S |
| Biotin-PEG3-NH2 | SC-8601 | C18H34N4O5S |
| Biotin-PEG2-NH2 | SC-8600 | C16H30N4O4S |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| PEG-12 | SC-1512 | C24H50O13 |
| PEG-11 | SC-1511 | C22H46O12 |
| PEG-10 | SC-1510 | C20H42O11 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Azido - PEG2 - TCA | SC-0066 | C6H9Cl3N4O2 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Azido - PEG2 - CM | SC-0064 | C5H10ClN3O |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| 2-Methyl-Glycerol | SC-0006 | C4H10O3 |
| 2-Stearoyl glycerol | SC-1171 | C21H42O4 |
| 2-Palmitoyl glycerol | SC-1170 | C19H38O4 |
| 2-Myristoyl glycerol | SC-1169 | C17H34O4 |
| 2-Lauroyl glycerol | SC-1168 | C15H30O4 |
| 2-Linoleoyl glycerol | SC-1167 | C21H38O4 |
| 2-Oleoyl-glycerol | SC-1162 | C21H40O4 |
| SH-6 | SC-0045 | C28H57O9P |
| SH-5 | SC-0044 | C29H59O10P |
| Ins(345)P3*3Na | 3-0-345-Na | C6H12Na3O15P3 |
| Ins(1)P*2K | 1-0-1-2K | C6H11K2O9P |
| myo-Inositol – trispyrophosphate | Pyro-Ins-Na | C6H8Na4O21P6 |
| Ins(123456)P6 | 6-0-123456-Na | C6H18O24P6 * xNa*yH2O |
| Ins(23456)P5*10Na | 5-0-23456-Na | C6H7Na10O21P5 |
| Ins(13456)P5*10Na | 5-0-13456-Na | C6H7Na10O21P5 |
| Ins(12456)P5*10Na | 5-0-12456-Na | C6H7Na10O21P5 |
| Ins(12356)P5*10Na | 5-0-12356-Na | C6H7Na10O21P5 |
| Ins(12345)P5*10Na | 5-0-12345-Na | C6H7Na10O21P5 |
| Ins(1345)P4*8Na | 4-0-1345-Na | C6H8Na8O18P4 |
| Ins(136)P3*6Na | 3-0-136-Na | C6H9Na6O15P3 |
| Ins(134)P3*6K | 3-0-134-K | C6H9K6O15P3 |
| Ins(345)P3*3K | 3-0-345-K | C6H12K3O15P3 |
| Ins(145)P3*6K | 3-0-145-K | C6H9K6O15P3 |
| Ins(145)P3*3Li | 3-0-145-Li | C6H12Li3O15P3 |
| Ins(145)P3*6Na | 3-0-145-Na | C6H9Na6O15P3 |
| Ins(135)P3*6Na | 3-0-135-6Na | C6H9Na6O15P3 |
| Ins(1245)P4*8Na | 4-0-1245-Na | C6H8Na8O18P4 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Bt3-Ins(356)P3 / PM | 3-2-356 | C42H69O30P3 |
| Bt3-Ins(346)P3 / PM | 3-2-346 | C42H69O30P3 |
| Bt3-Ins(146)P3 / PM | 3-2-146 | C42H69O30P3 |
| Bt3-Ins(135)P3 / PM | 3-2-135 | C42H69O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| Bt2-Ins(3456)P4 / PM | 4-2-3456 | C46H76O36P4 |
| Bt2-Ins(1456)P4 / PM | 4-2-1456 | C46H76O36P4 |
| Bt2-Ins(1345)P4 / PM | 4-2-1345 | C46H76O36P4 |
| Bt2-Ins(1356)P4 / AM | 4-1-1356 | C38H60O36P4 |
| Bt3-Ins(356)P3 / AM | 3-1-356 | C36H57O30P3 |
| Bt3-Ins(346)P3 / AM | 3-1-346 | C36H57O30P3 |
| Bt3-Ins(146)P3 / AM | 3-1-146 | C36H57O30P3 |
| Bt3-Ins(134)P3 / AM | 3-1-134 | C36H57O30P3 |
| Bt3-Ins(136)P3 / AM | 3-1-136 | C36H57O30P3 |
| Bt3-Ins(135)P3 / AM | 3-1-135 | C36H57O30P3 |
| Bt3-Ins(145)P3 / AM | 3-1-145 | C36H57O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| caged-Ins(145)P3O6 | cag-6-145 | C15H18NO19P3Na6 |
| caged-Ins(145)P3 P4 | cag-0-145 | C14H19NO17P3Na3 |
| PtdIns(345)P3 | Ptd-0-345-16 | C41H82O22P4 |
| PtdIns(45)P2 | Ptd-0-45-16 | C41H81O19P3 |
| PtdIns(34)P2 | Ptd-0-34-16 | C41H81O19P3 |
| PtdIns(5)P | Ptd-0-5-16 | C41H80O16P2 |
| PtdIns(4)P | Ptd-0-4-16 | C41H80O16P2 |
| PtdIns(3)P | Ptd-0-3-16 | C41H80O16P2 |
| PtdIns(1)P | Ptd-0-1-16 | C41H79O13P |
| D-myo-Inositol-1,2-O-cyclohexylidene | SC-0088 | C12H20O6 |
| 23:45- diisopropylidene-myo-Inositol | SC-0079 | C12H20O6 |
| 12:56- diisopropylidene-myo-Inositol | SC-0078 | C12H20O6 |
| D-myo-Inositol-2,3-O-cyclohexylidene | SC-0077 | C12H20O6 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| 2,3:4,5-Di-O-Iso-1,6-Di-O-Benzyl-Ins | IOB-Ins-2345 | C26H32O6 |
| 1,2:5,6-Di-O-Iso-3,4-Di-O-Benzyl-Ins | IOB-Ins-1256 | C26H32O6 |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| DEAC-dUTP | SC-9002 | C26H31N4O17P3 |
| 35-PAPS-TEA | SC-9000-TEA | C10H15N5O13P2S x 4 C6 H15 N |
| ACPPS-TEA | SC-0068 | C10H13N5O12P2S + C6H5N |
| 25-PAPS-Li | SC-9001-Li | C10H11Li4N5O13P2S |
| 35-PAPS-Li (CAS: 102029-54-9) | SC-9000-Li | C10H11Li4N5O13P2S |
| EdU | SC-0040 | C11H12N2O5 |
| EdUTP-TEA | SC-0039 | C11H15N2O14P3 * 4(C6H15N) |
| EdUTP | SC-0038 | C11H15N2O14P3 |
| 2'-PAP | SC-0037 | C10H17N5O10P2 |
| 2'-PAP-Na | SC-0036 | C10H15N5Na2O10P2 |
| 3'-PAP-Na | SC-0034 | C10H15N5Na2O10P2 |
| 3'-PAP | SC-0035 | C10H17N5O10P2 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Didechloro Vancomycin | SC-1605 | C66H77N9O24 |
| Vancomycin Impurity A | SC-1601 | C65H73Cl2N9O24 |
| Vancomycin Impurity D | SC-1604 | C59H62Cl2N8O22 |
| Vancomycin Impurity C | SC-1603 | C53H52Cl2N8O17 |
| Vancomycin Impurity B | SC-1602 | C66H74Cl2N8O25 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Podophyllotoxin Derivate | SC-0025 | C21H20O8 |
| Podophyllotoxin Derivate | SC-0026 | C21H21NO7 |
| Clopidogrel Impurity 4 | SC-0099 | C16H16ClNO2S * H2SO4 |
| Gestodene Impurity E | SC-0028 | C21H24O3 |
| Fidaxomicin Metabolite OP-1118 | SC-1158 | C48H68Cl2O17 |
| Prasugrel metabolite M6-d3 (stabilzed) | SC-0093 | C27H25D3FNO5S * HCl |
| Prasugrel metabolite M6 | SC-0092 | C19H22FNO3S |
| Clopidogrel Impurity C | SC-0087 | C16H18ClNO2S |
| Clopidogrel Impurity 3 | SC-0086 | C15H17Cl2NO2S |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| Prasugrel active metabolite M3 HCl (stabilized) | SC-0029 | C27H28FNO5S * HCl |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Methyl 4-(2-hydroxyethyl)benzoate-13C6,2D (Ring-13C6,Ethyl-1,2-D2) | SC-0080 | C4 13C6 H10 D2 O3 |
| Anthracene 13C6 | SC-0074 | 13C6C8H8 |
| Phenanthrene 13C6 | SC-0073 | 13C6C8H8 |
| Naphthalene 13C10 | SC-0072 | 13C10H8 |
| Naphthalene 13C6 | SC-0071 | 13C6C4H8 |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite | SC-0091 | C9H18ClN2OP |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(2-cyanoethyl) ester | SC-0061 | C12H22N3O2P |
| Phosphoramidous acid, N,N-bis(1-methylethyl)-, bis(phenylmethyl) ester | SC-1165 | C20 H28 N O2 P |
| Phosphorodiamidous acid. N.N.N'.N'-tetrakis(1-methylethyl)-. phenylmethyl ester | SC-0060 | C19 H35 N2 O P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. 2-cyanoethyl [1-(2-nitrophenyl)ethyl] ester) | SC-0059 | C17 H26 N3 O4 P |
| Dichloro N,N-Diisopropylphosphoramidite | SC-0058 | C6 H14 Cl2 N P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(9H-fluoren-9-ylmethyl) ester | SC-0057 | C34 H36 N O2 P |
| Di-tert-butyl chloromethyl phosphate | SC-0011 | C9H20ClO4P |
| Di-benzyl chloromethyl phosphate | SC-0010 | C15H16ClO4P |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| D-Serine-O-phosphate | SC-1810 | C3H8NO6P |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Menaquinone 8 / MK 8:8 | SC-1230 | C51H72O2 |
| Allyl-Maleimide | SC-1121 | C7H7NO2 |
| Nor-cisapride Derivative | SC-1161 | C17H25Cl2N3O3 |
| AlK - L - Lysine - HCl-salt | SC-8012 | C10H18N2O4* HCl |
| 4-methyl-2,2-bis(trifluoromethyl)oxazolidin-5-one | SC-0098 | C6H5F6NO2 |
| 3-(5-oxo-2,2-bis(trifluoromethyl)oxazolidin-4-yl)propanoic acid | SC-0097 | C8H7F6NO4 |
| 7-(diethylamino)-4-(hydroxymethyl)-coumarin / DEACM | SC-0096 | C14H17NO3 |
| 3-bromo-4-methyl-7-(diethylamino)-coumarin | SC-0095 | C14H16BrNO2 |
| Xanthohumol | SC-0094 | C21H22O5 |
| IEPOX 4 | SC-0090 | C5H10O3 |
| IEPOX 3 | SC-0089 | C5H10O3 |
| 2-C-Methyl-L-Threitol | SC-0085 | C5H12O4 |
| 2-C-Methyl-D-Threitol | SC-0084 | C5H12O4 |
| 2-C-Methyl-L-Erythritol | SC-0083 | C5H12O4 |
| 2-C-Methyl-D-Erythritol | SC-0082 | C5H12O4 |
| 3-Amino-7-(diethylamino)-coumarine | SC-0081 | C13 H16 N2 O2 |
| Chloromethylpropionate | SC-1164 | C4H7ClO2 |
| 2-(2-fluoro-2-methylpropoxy)-2-methylpropan-1-ol | SC-1163 | C8H17FO2 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| Y-27632 | SC-0048 | C14H21N3O *2HCl |
| H-1152 | SC-0053 | C16H21N3O2S*2HCl |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| TCO* - NHS carbonate / EQUATORIAL isomer | SC-8071 | C13H17NO5 |
| TCO* - NHS carbonate / AXIAL isomer | SC-8070 | C13H17NO5 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
<艾美捷科技代理CSCRIE Corporation品牌全系列产品
CSCRIE Corporation成立于2020年3月,公司致力于解决生命科学领域研究人员面临的问题,通过运用多年来积累的精密冲压技术、胶带与薄膜层压技术以及激光微加工技术,为生命科学市场提供各类产品。此外,CSCRIE公司还承接原创细胞培养板以及微流控芯片等带有微孔与微槽的产品的试制与开发。CSCRIE公司的产品包括样品过滤、标签与密封(多种应用),特种微孔板等产品。

▍CSCRIE产品线
● 样品过滤
CSCRIE的离心管用密封式滤器和96孔微孔板滤器可助您快速完成样品过滤。此外,其底部带滤网的96孔或384孔微孔板非常适合高通量筛选。
| 产品名称 | 产品描述 |
| Mesh seal for sample filtration (for 1.5 mL and 5 mL tubes) | This seal type mesh (strainer) is designed for rapid sample filtration on 1.5 mL and 5 mL tubes. |
| Mesh seal for sample filtration (for 15 mL tube) | This seal type mesh (strainer) is designed for rapid sample filtration on 15 mL tube. |
| Mesh seal for sample filtration (for 50 mL tube) | This seal type mesh (strainer) is designed for rapid sample filtration on 50 mL tube. |
| Mesh seal for sample filtration (for 96 well plate) | This seal type mesh (strainer) is designed for rapid sample filtration on 96 well plate. |
| Mesh bottom filtration plate (96- & 384-well plate) | This mesh bottom filtration plate is designed for rapid and highthrouput sample filtration from 96- or 384-well plate by centrifuge. |
● 标签与密封(多种应用)
| 产品名称 | 产品描述 |
| Sealing Film for real-time PCR | 低自体荧光压敏 PCR 板密封膜,兼容 PCR 和实时荧光定量 PCR (real-time PCR)。经 γ 射线灭菌,具备良好的耐热性(-20℃ 至 110℃)。 |
| Hydrophobic PDMS Sheet (Ultra-thin type) | 超薄高精度疏水性 PDMS(聚二甲基硅氧烷)薄膜,专注于活菌、活细胞及 DNA 的分析与培养。 |
| Hydrophilic PDMS Sheet | 具有持久亲水性的 PDMS 片材,适用于多种研究应用。 |
| Microplate note seal | 这是一款独特的密封膜,可在 96 孔微孔板上直接书写文字。 |
| Anti-Frost Label Protector | 防冻标签保护膜,可全面保护样品管上的标记,例如防霜冻、防乙醇等。 |
| Microplate seal for 96-well (cutting off type) | 微孔板封膜,可沿每行(8孔)的压痕线切割,便于在样本注入期间及之后反复开合。 |
● 特种微孔板
<| 产品名称 | 产品描述 |
| Microplate without bottom plate | 该微孔板无孔底部分,可根据研究应用需求在底部结合任意材料。其产品系列包括 6 孔、24 孔、96 孔及 384 孔规格。 |
● 其他产品
<| 产品名称 | 产品描述 |
| CS Mouse Wound Splint | CS 小鼠伤口夹板在与皮肤接触侧设有胶带层,因此固定夹板时无需额外使用粘合剂或胶水,与传统夹板相比,固定操作更便捷。 |
| CS IHC-Fencing Seal | 这是一种环绕载玻片上组织切片的疏水密封结构,可防止抗体、磷酸盐缓冲液(PBS)等试剂在组织标本上发生外溢或混合。 |

艾美捷科技代理SeraCare对照及参比物质。
艾美捷科技有限公司,自2018年与SeraCare(现隶属于LGC Clinical Diagnostics)合作以来,长期为中国客户提供包括SeraSeq系列参比物质,领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质,可以用于任何研发阶段,以确保临床基因组学检测结果的准确性。
SeraCare参比物质涵盖的范围:
1)Next Generation Sequencing
2)Sanger Sequencing
3)Real-time PCR and digital PCR (dPCR)
4)Microarray
主要特点
1)Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions
2)Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs
3)Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE
4)Manufactured in cGMP-compliant, ISO 13485-certified facilities
5)Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers
| 参比物质 | 货号 | 规格 |
| Seraseq® Whole Transcriptome RNA Seq Mix | 0710-2129 | 1 x 20 µl |
| Seraseq® Unmethylated ctDNA Mutation Mix | 0710-3088 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 7 HC | 0710-0095 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 10 HC | 0710-0094 | 1 x 25 µl |
| Seraseq® Tri-Level Tumor Mutation DNA Mix v2 HC | 0710-0097 | 1 x 25 µl |
| Seraseq® TNA (DNA/RNA) WT Mix | 0710-1580 | 2 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +6 copies | 0710-2867 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +3 copies | 0710-2866 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +12 copies | 0710-2868 | 1 x 20 µl |
| Seraseq® NTRK Fusion RNA Mix | 0710-1696 | 1 x 20 µl |
| Seraseq® Myeloid Mutation DNA Mix | 0710-0408 | 1 x 25 µl |
| Seraseq® Myeloid Fusion RNA Mix | 0710-0407 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix WT | 0710-2646 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF1% | 0710-2649 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.5% | 0710-2648 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.1% | 0710-2647 | 1 x 25 µl |
| Seraseq® MSI Reference Panel Mix AF5% | 0710-1675 | 2 x 15 µl |
| Seraseq® MSI Reference Panel Mix AF20% | 0710-1676 | 2 x 15 µl |
| Seraseq® Methylated ctDNA Mutation Mix | 0710-3089 | 1 x 25 µl |
| Seraseq® Lymphoma DNA Mutation Mix | 0710-2203 | 1 x 25 µl |
| Seraseq™ Lung & Brain CNV Mix, + 6 copies | 0710-0415 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 3 copies | 0710-0414 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 12 copies | 0710-0416 | 1 x 20 µl |
| Seraseq® HRD gDNA Negative Mix | 0710-2881 | 2 x 20 µl |
| Seraseq® HRD gDNA Low-Positive Mix | 0710-2880 | 2 x 20 µl |
| Seraseq® HRD gDNA High-Positive Mix | 0710-2879 | 2 x 20 µl |
| Seraseq® gDNA TMB Reference Panel Mix | 0710-2463 | 5 x 20 µl |
| Seraseq® gDNA TMB Mix Score 9 | 0710-1325 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 7 | 0710-1326 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 26 | 0710-1323 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 20 | 0710-1324 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 13 | 0710-1586 | 2 x 10 µl |
| Seraseq® gDNA MSI-High Mix | 0710-1670 | 1 x 20 µl |
| Seraseq® gDNA BRCA1/2 LGR Somatic Mutation Mix | 0730-0567 | 1 x 25 µl |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µl |
| Seraseq® Fusion RNA Mix v4 | 0710-0497 | 1 x 25 µl |
| Seraseq® FFPE WT (DNA/RNA) Reference Material | 0710-0137 | 1 x 10 µm |
| Seraseq® FFPE TMB RM Score 9 | 0710-1308 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 7 | 0710-1310 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 26 | 0710-1307 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 20 | 0710-1309 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 13 | 0710-1618 | 2 x 10 um |
| Seraseq® FFPE Solid Tumor CNV Reference Materials | 0710-2865 | 1 x 10 µm |
| Seraseq® FFPE NTRK Fusion RNA Reference Material | 0710-1031 | 1 x 10 µm |
| Seraseq® FFPE MSI-High RM | 0710-2236 | 1 x 10 um |
| Seraseq® FFPE Lymphoma DNA Reference Material | 0710-2202 | 1 x 10 µm |
| Seraseq® FFPE HRD Negative RM | 0710-2644 | 1 x 10 µm |
| Seraseq® FFPE HRD Low-Positive RM | 0710-2645 | 1 x 10 µm |
| Seraseq® FFPE HRD High-Positive RM | 0710-2643 | 1 x 10 µm |
| Seraseq® FFPE Tumor Fusion RNA v4 Reference Material | 0710-0496 | 1 x 10 µm |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® ctDNA Reference Material v2 WT | 0710-0208 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF2% | 0710-0203 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF1% | 0710-0204 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.5% | 0710-0205 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.125% | 0710-0207 | 1 x 5 mL |
| Seraseq® ctDNA Mutation Mix v2 WT | 0710-0144 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF2% | 0710-0139 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF1% | 0710-0140 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.5% | 0710-0141 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.25% | 0710-0142 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.125% | 0710-0143 | 1 x 25 µl |
| Seraseq® ctDNA MRD Panel Mix | 0710-2146 | 4 x 20 µl |
| Seraseq® ctDNA Complete™ Reference Material WT (0%) | 0710-0674 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF5% | 0710-0669 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF2.5% | 0710-0670 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF1% | 0710-0671 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.5% | 0710-0672 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.1% | 0710-0673 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Mutation Mix WT (0%) | 0710-0533 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF5% | 0710-0528 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF2.5% | 0710-0529 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF1% | 0710-0530 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.5% | 0710-0531 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.1% | 0710-0532 | 1 x 25 µl |
| Seraseq® Compromised FFPE WT (DNA/RNA) RM | 0710-1710 | 1 x 10 µm |
| Seraseq® Compromised FFPE Tumor DNA RM | 0710-1492 | 1 x 10 µm |
| Seraseq® Breast CNV Mix, + 6 copies | 0710-0412 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 3 copies | 0710-0411 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 12 copies | 0710-0413 | 1 x 20 µl |
| Seraseq® Blood TMB Mix Score 7 | 0710-2087 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 26 | 0710-2090 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 20 | 0710-2089 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 13 | 0710-2088 | 3 x 20 µl |
| Seraseq® Turner Syndrome (XO) Reference Material | 0720-0952 | 1 x 1 mL |
| Seraseq® Trisomy 21 Male-Matched Reference Material | 0720-0167 | 1 x 1 mL |
| Seraseq® Trisomy 21 Female-Matched Reference Material | 0720-0168 | 1 x 1 mL |
| Seraseq® Trisomy 18 Male-Matched Reference Material | 0720-0171 | 1 x 1 mL |
| Seraseq® Trisomy 18 Female-Matched Reference Material | 0720-0172 | 1 x 1 mL |
| Seraseq® Trisomy 13 Male-Matched Reference Material | 0720-0779 | 1 x 1 mL |
| Seraseq® Trisomy 13 Female-Matched Reference Material | 0720-0780 | 1 x 1 mL |
| Seraseq® Triple X Syndrome (XXX) Reference Material | 0720-1069 | 1 x 1 mL |
| Seraseq® PGT-A Trisomy 21 Reference Material | 0720-0775 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 18 Reference Material | 0720-0776 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 13 Reference Material | 0720-0777 | 1 x 10 µl |
| Seraseq® PGT-A Euploid Reference Material | 0720-0778 | 1 x 10 µl |
| Seraseq® Klinefelter Syndrome (XXY) Reference Material | 0720-0953 | 1 x 1 mL |
| Seraseq® Jacobs Syndrome (XYY) Reference Material | 0720-0954 | 1 x 1 mL |
| Seraseq® Euploid Male-Matched Reference Material | 0720-0169 | 1 x 1 mL |
| Seraseq® Euploid Female-Matched Reference Material | 0720-0170 | 1 x 1 mL |
| Seraseq® 22q11 Male-Matched Reference Material | 0720-0173 | 1 x 1 mL |
| Seraseq® 22q11 Female-Matched Reference Material | 0720-0174 | 1 x 1 mL |
| Seraseq® Inherited Cancer DNA Mix v1 | 0730-0003 | 1 x 200 µL |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µL |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® Cardiomyopathy Reference Material | 0740-0021 | 1 x 200 µL |

Columbia Biosciences 公司成立于2007年,主要生产天然荧光蛋白、抗体交联物及检测试剂盒。Columbia Biosciences具有成熟的,对微藻生物的培养、分离、纯化、及藻类荧光蛋白基团接合技术,并将其应用于生命科学产品、诊断工具中,并推广到全世界。
Columbia Biosciences, founded in 2007, manufactures natural fluorescent proteins, antibody conjugates and assay kits. Columbia's expertise lies in the ability to integrate microalgae cultivation with the isolation, purification and conjugation of algal protein fluorophores. The company's fluorophores are integrated into a large number of life science products and diagnostic tools and, are distributed globally.
Columbia Biosciences的主要产品包括:
Cyclic AMP Kit
PHYCOBILIPROTEINS AND PERCP
TR-FRET REAGENTS
ANTIBODY CONJUGATES
Conjugation Kits
Europium Conjugates
Isotype Controls
POC Reagents
" data-original="http://antibody.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Columbia Biosciences"> Columbia Biosciences
GlycoTech公司成立于1991年,是世界上最负盛名的糖生物学公司之一。Glycotech的使命是通过糖基团与它们受体之间的互相作用,发现和筛选出一系列具有药物潜力的化合物。GlycoTech还建立了世界上最大的稀有碳水化合物试剂库之一。
GlycoTech was founded in 1991 and remains today as one of the premier companies focusing on the biological functions and medical applications of glycoconjugates. The company has established its own research programs and has developed a large intellectual property portfolio. Through its catalog business, GlycoTech has also established one of the largest libraries of rare carbohydrate reagents and technologies worldwide.
GlycoTech的主要产品包括:
Cancer Diagnostics
Human Selectins
Carbohydrate Polymers
Carbohydrate Antibodies
HSA/BSA Conjugates
Cell Adhesion Apparatus
Human Endothelial Cells
Carbohydrates / Reagents
Carbohydrate Adsorbents
Research Protocols
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://antibody.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="GlycoTech"> GlycoTech
艾美捷科技代理Cali-Bio品牌。
Cali-Bio成立于 2009 年,总部位于美国加利福尼亚州,是一家专注于为生命科学研究和生物制药行业提供高质量试剂、细胞培养工具和相关服务的公司。Cali-Bio公司专注于开发和生产高质量的生物试剂和细胞培养工具,产品涵盖细胞培养基、血清、生长因子、细胞分离试剂和定制服务等。Cali-Bio 的产品被广泛应用于细胞生物学、免疫学、癌症研究、干细胞研究和生物制药等领域。Cali-Bio公司主要产品包括:
(1)细胞培养基
经典培养基,提供 DMEM、RPMI-1640、MEM 等常用培养基。
无血清培养基,适用于特定细胞类型的无血清培养,减少批次间差异。
干细胞培养基,支持干细胞的自我更新和分化。
(2)血清和补充剂
胎牛血清(FBS),高质量胎牛血清,适用于多种细胞培养。
马血清、人血清,用于特定细胞类型的培养。
生长因子和细胞因子,包括 EGF、FGF、IGF 等,支持细胞生长和功能维持。
(3)细胞分离和传代试剂
胰酶和细胞解离试剂,用于细胞传代和单细胞分离。
细胞冻存液,提供高效的细胞冻存解决方案,确保细胞存活率。
(4)细胞检测和分析工具
细胞活力检测试剂,如 MTT、CCK-8 等,用于评估细胞活力和增殖。
细胞凋亡检测试剂,用于检测细胞凋亡和坏死。
细胞迁移和侵袭实验试剂,支持癌症研究和药物筛选。

瑞典Agrisera公司成立于1980年,长期以来,公司致力于植物/环境科学研究中所需蛋白抗体研发与销售,主要集中于模式之物及其他植物的生理、病理相关的蛋白抗体。Agrisera 公司以提供高品质、优服务在欧洲树立了优秀的品牌形象,并成为瑞典 Umeå Plant Science Centre的抗体供货商,同时还积极拓展全球市场,每年都有大批采用该公司抗体产品的高质量研究论文发表于各类学术刊物,受到全球科研工作者的一致认可。Agrisera的所有抗体分两大类:植物及藻类的抗体,以及细菌、真菌、昆虫、鱼等动物类抗体,植物领域的抗体涵盖Arabidopsis thaliana、Hordeum vulgare、Chlamydomonas reinhardtii、Cyanobacteria、Physcomitrella patens、Oryza sativa、Populus sp、Conifers等多个物种。
Agrisera is a Swedish company specializing in polyclonal and monoclonal antibody production, offering an extensive collection of primary antibodies and over 2000 secondary antibodies for various applications and in various quantities, all available online. Over 30 years in the antibody business have taught us a lot and we are proud to say there are few problems we cannot help you to solve. Our experienced scientific staff are on hand to answer all your queries promptly.
Agrisera公司的主要产品包括:
Plant/Algal antibodies
Animal/Human antibodies
Bacterial/Fungal antibodies
Secondary antibodies
Rapid Western Blotting
Detection reagents
" data-original="http://antibody.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Agrisera"> Agrisera地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:15172431432
邮箱:sales@amyjet.com
0.3522